23 / 38
LENVATINIB
Capdevila J, et al. Ann Oncol. 2018;29(Suppl_8):viii467-viii478
TALENT Trial
: A phase II Trial to Assess the efficacy of LENvatinib in metastatic neuroendocrine Tumors(GETNE 1509)
N = 110 patients
Adv/Metastatic G1/G2 NET
Cohort A
PANCREAS: After progression to a previous targeted agent
Cohort B
GASTROINTESTINAL TRACT: After progression to somatostatin analogs
Lenvatinib
24 mg /24h
TARGETED AGENTS